CN109045045A - A kind of active ingredient of Chinese herbs composition for treating cardiovascular and cerebrovascular disease - Google Patents
A kind of active ingredient of Chinese herbs composition for treating cardiovascular and cerebrovascular disease Download PDFInfo
- Publication number
- CN109045045A CN109045045A CN201810921299.2A CN201810921299A CN109045045A CN 109045045 A CN109045045 A CN 109045045A CN 201810921299 A CN201810921299 A CN 201810921299A CN 109045045 A CN109045045 A CN 109045045A
- Authority
- CN
- China
- Prior art keywords
- composition
- active ingredient
- cerebrovascular disease
- treating cardiovascular
- chinese herbs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of active ingredient of Chinese herbs composition for treating cardiovascular and cerebrovascular disease, the composition is gone obtained by two or three of mixing in the peppery diketone of hydroxyl ginger by pachymic acid, honokiol and 10-.The present invention is under the combination of optimal compatibility, and compatibility or three component compatibilities can significantly reduce TC, TG and LDL-C content and increase the content of HDL-C two-by-two.Two-by-two after compatibility, blank control group level cannot be fully achieved in four kinds of indexs, but is on close level with blank control group.Four kinds of finger target values can then be reduced or be increased to blank control level by three component compatibilities.
Description
Technical field
The present invention relates to field of traditional Chinese medicine preparations, and in particular to a kind of active ingredient of Chinese herbs combination for treating cardiovascular and cerebrovascular disease
Object.
Background technique
Atherosclerosis (atherosclerosis, AS) refers to deposited fat on ductus arteriosus wall, because of interior film outward appearance
It is yellow-white, similar congee sample, therefore it is atherosis.The deposition of these lipids makes artery wall thickening, flexibility decrease, to make
Blood vessel is hardened, therefore referred to as atherosclerosis.Cholesterol metabolism abnormity be cause the significant risk of atherosclerotic lesions because
Element, epidemiological study have confirmed that low-density lipoprotein (LDL) or low density lipoprotein cholesterol (LDL-C) are artery congee
The important pathogenic factor of sample hardening, and the horizontal generation with atherosclerosis of plasma hdl cholesterol (HDL-C)
Negatively correlated, triglyceride (TG) and total cholesterol (TC) raising are the independent hazard factors for causing coronary heart disease.Nowadays, recognize
It is existed simultaneously for the abnormal reduction increased with HDL-C of LDL-C, TG, TC, is a kind of blood lipoprotein syndrome of high risk,
Referred to as atherogenic lipoprotein phenotype.Atherosclerosis is coronary heart disease, cerebral infarction, peripheral vascular disease and high blood
The main reason for cardiovascular and cerebrovascular diseases such as pressure.
The Western medicine lipid-lowering effects such as existing Statins (Statin), fibrates (Fibrate) are obvious, but long-term administration is to liver
It is big (only about 28% crowd is applicable in) with musclar toxicity effect.Ezetimibe (Ezetimibe) and bile acid sequestrant etc. due to
The mechanism of action is single, and target user is then less.And compound of Chinese herbal medicine hyperlipidemia and its complication have a good effect, but by
It is complex in traditional Chinese medicine compound ingredient, there is the action character of more compositions, too many levels, multiple target point, quality is difficult to control, from
And limit popularization and use of the Chinese traditional medicines depressing lipid in wider scope.The single active ingredient of Chinese herbs of ingredient is although quality controllable, but
It is that therapeutic effect has a long way to go compared with Chinese medicine compound prescription.In recent years, tcm components are with its " with strong points, safe and effective, quality controllable "
As the research tendency of the modernization of Chinese medicine, the main active of ingredients in Chinese medicine compound prescription is combined, not using it
Same mechanism of action plays the curative effect of preferable even better than Chinese medicine compound prescription.
Poria cocos is one of common traditional Chinese medicine ingredients in China, and the civil saying for having " ten medicines, nine Poria cocos ", Poria cocos is Polyporaceae
The dry sclerotia of fungi Poria cocos, traditional Chinese medicine theory think that Poria cocos has effects that inducing diuresis for removing edema, invigorating the spleen excreting dampness, antitoxic heart-soothing and sedative.Fu
Siberian cocklebur chemical component mainly has pachymaran and su-fuling etc., and su-fuling is one group of tetracyclic triterpenes small molecule compound, with acid
Form exists, and pachymic acid (pachymic acid, PA) is one of its most important ingredient.Researches show that PA can be by directly pressing down
Phospholipase A2 processed
(phospholipase A2, PLA2) limits OxLDL ELISA modification, and then inhibits atherosclerosis
Formation.
Cortex Magnoliae Officinalis is a kind of traditional Chinese medicine in China, there is certain long history, with significant antibacterial activity, cardiovascular protection
The extensive effect such as function, antidepression.Data at home and abroad report about its main component HK effect mainly have antibacterial, antiulcer,
Calm nervous centralis, relaxed muscle, extend sleep, decompression, treatment gastrointestinal disease, antianxiety, it is antitumor the effects of.Research is aobvious
Show, honokiol (honokoil, HK) can be by binding directly simultaneously peroxide activator enzyme body proliferator activated receptor γ
(peroxisome
Proliferators-activated receptors, PPAR γ), to show the function such as hypoglycemic, reducing blood lipid
Effect.
It is a kind of natural that 10- present in ginger, which removes the peppery diketone of hydroxyl ginger (10-dehydrogingerdione, DHG),
CETP inhibitor, cholesterol ester transfer protein (cholesterol ester transfer protein, CETP) are that one kind exists
The important molecule to play the role of a nucleus in HDL metabolism, HDL-C level can be increased up to 50% after being inhibited, and can be significantly changed
The pathologic process of atherosclerosis.
Although the related pharmacological mechanism of three kinds of active constituents has been reported that, however, not carried out reasonable compatibility still.
Summary of the invention
To solve the above problems, the present invention provides a kind of active ingredient of Chinese herbs composition for treating cardiovascular and cerebrovascular disease,
Lipid-loweringing purpose is realized by carrying out reasonable compatibility to PA, HK and DHG, can reduce side effect, while remaining Chinese medicine multiple groups
Divide disease-resistant pharmacological mechanism.
To achieve the above object, the technical scheme adopted by the invention is as follows:
A kind of active ingredient of Chinese herbs composition for treating cardiovascular and cerebrovascular disease, the composition is by pachymic acid (PA), magnolia obovata
Phenol (HK) and 10- are gone obtained by two or three of mixing in the peppery diketone of hydroxyl ginger (DHG).
Further, the composition is made of the raw material of following mass percent:
Pachymic acid (PA), honokiol (HK) and 10- remove the quality percentage of the peppery diketone of hydroxyl ginger (DHG) in the composition
Than being respectively 20~50%, 5~30% and 10~40%.
Preferably, the composition is by pachymic acid (PA), honokiol (HK) 3:1 in mass ratio mixing gained.
Preferably, the composition goes the peppery diketone of hydroxyl ginger (DHG) 3:2 in mass ratio to mix institute by pachymic acid (PA), 10-
?.
Preferably, the composition goes the peppery diketone of hydroxyl ginger (DHG) 1:2 in mass ratio to mix institute by honokiol (HK), 10-
?.
Preferably, the composition goes the peppery diketone of hydroxyl ginger (DHG) by quality by pachymic acid (PA), honokiol (HK), 10-
Gained is mixed than 3:1:2.
The invention has the following advantages:
Optimal compatibility combination under, two-by-two compatibility or three component compatibilities can significantly reduce TC, TG and LDL-C content with
And increase the content of HDL-C.Two-by-two after compatibility, four kinds of indexs cannot be fully achieved blank control group level, but with blank pair
According to being on close level for group.Four kinds of finger target values can then be reduced or be increased to blank control level by three component compatibilities.
Specific embodiment
In order to which objects and advantages of the present invention are more clearly understood, the present invention is carried out with reference to embodiments further
It is described in detail.It should be appreciated that the specific embodiments described herein are merely illustrative of the present invention, it is not used to limit this hair
It is bright.
Kun Ming mice is after 4 weeks feed, fasting 12h.Blank control group (feeding basal feed), hyperlipidemia pair are set
According to group (feeding high lipid food), one pack system experimental group and component compatibility experimental group.Free water and feed during experiment, daily with
8mg/kg dosage in early morning and at dusk respectively carry out intraperitoneal injection 1 time (0.2mL), continuous 2 weeks.After the last administration, all animals are prohibited
12h is eaten, eyeground vein takes blood, and blood the water-bath 30min at 37 DEG C, 3500r/min are centrifuged 15min, separate serum, use kit
Measure TC, TG, HDL-C, LDL-C content.Medicament is all made of aqueous dissolution or the suspension of Tween 80 and ethyl alcohol, wherein tween
80 and ethyl alcohol final concentration less than 0.1%.
1 one pack system of table and component compatibility experimental result (n=10)
Note: variance analysis and Duncan Multiple range test are carried out using SPSS ver.16.0 software (IBM, the U.S.)；Each component
Ratio be mass ratio.
Seen from table 1, above-mentioned compatibility combination under, two-by-two compatibility or three component compatibilities can significantly reduce TC, TG and
LDL-C content and the content for increasing HDL-C.Two-by-two after compatibility, blank control group level cannot be fully achieved in four kinds of indexs, but
It is on close level with blank control group.Four kinds of finger target values can then be reduced or be increased to blank control water by three component compatibilities
It is flat.
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, without departing from the principle of the present invention, it can also make several improvements and retouch, these improvements and modifications are also answered
It is considered as protection scope of the present invention.
Claims (6)
1. a kind of active ingredient of Chinese herbs composition for treating cardiovascular and cerebrovascular disease, which is characterized in that the composition by pachymic acid and
Magnolol, 10- are gone obtained by two or three of mixing in the peppery diketone of hydroxyl ginger.
2. a kind of active ingredient of Chinese herbs composition for treating cardiovascular and cerebrovascular disease as described in claim 1, which is characterized in that should
Composition is made of the raw material of following mass percent:
Pachymic acid 20~50%；Honokiol 5~30%；10- removes the peppery diketone 10~40% of hydroxyl ginger.
3. a kind of active ingredient of Chinese herbs composition for treating cardiovascular and cerebrovascular disease as described in claim 1, which is characterized in that should
Composition is by pachymic acid (PA), honokiol (HK) 3:1 in mass ratio mixing gained.
4. a kind of active ingredient of Chinese herbs composition for treating cardiovascular and cerebrovascular disease as described in claim 1, which is characterized in that should
Composition removes the peppery diketone of hydroxyl ginger (DHG) 3:2 in mass ratio mixing gained by pachymic acid (PA), 10-.
5. a kind of active ingredient of Chinese herbs composition for treating cardiovascular and cerebrovascular disease as described in claim 1, which is characterized in that should
Composition removes the peppery diketone of hydroxyl ginger (DHG) 1:2 in mass ratio mixing gained by honokiol (HK), 10-.
6. a kind of active ingredient of Chinese herbs composition for treating cardiovascular and cerebrovascular disease as described in claim 1, which is characterized in that should
Composition removes the peppery diketone of hydroxyl ginger (DHG) 3:1:2 in mass ratio mixing gained by pachymic acid (PA), honokiol (HK), 10-.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810921299.2A CN109045045B (en) | 2018-08-14 | 2018-08-14 | A Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810921299.2A CN109045045B (en) | 2018-08-14 | 2018-08-14 | A Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109045045A true CN109045045A (en) | 2018-12-21 |
| CN109045045B CN109045045B (en) | 2020-10-09 |
Family
ID=64683889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810921299.2A Active CN109045045B (en) | 2018-08-14 | 2018-08-14 | A Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109045045B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112138053A (en) * | 2020-11-05 | 2020-12-29 | 西北民族大学 | A pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, and its preparation method |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140141082A1 (en) * | 2012-11-16 | 2014-05-22 | Song Gao | Compositions Containing Enriched Natural Crocin and/or Crocetin, and Their Therapeutic or Nutraceutical Uses |
| CN104000876A (en) * | 2014-06-18 | 2014-08-27 | 青岛市市立医院 | Composition of mangnolia officinalis and gingerol and application thereof |
| CA2970651A1 (en) * | 2014-12-12 | 2016-06-16 | Ojai Energetics Pbc | Microencapsulated cannabinoid compositions |
| CN105749103A (en) * | 2016-04-05 | 2016-07-13 | 邱发龙 | Pharmaceutical preparation for treating narcolepsy and preparation method thereof |
| CN106074582A (en) * | 2016-07-12 | 2016-11-09 | 昆明学院 | 4 cyano group β D glucoside compounds purposes in the medicine preparing treatment anxiety neurosis |
| CN108066439A (en) * | 2017-12-24 | 2018-05-25 | 湖北藻上好生物科技有限公司 | A kind of preparation method of the reducing blood lipid native compound group based on solution fermentation |
-
2018
- 2018-08-14 CN CN201810921299.2A patent/CN109045045B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140141082A1 (en) * | 2012-11-16 | 2014-05-22 | Song Gao | Compositions Containing Enriched Natural Crocin and/or Crocetin, and Their Therapeutic or Nutraceutical Uses |
| CN104000876A (en) * | 2014-06-18 | 2014-08-27 | 青岛市市立医院 | Composition of mangnolia officinalis and gingerol and application thereof |
| CA2970651A1 (en) * | 2014-12-12 | 2016-06-16 | Ojai Energetics Pbc | Microencapsulated cannabinoid compositions |
| CN105749103A (en) * | 2016-04-05 | 2016-07-13 | 邱发龙 | Pharmaceutical preparation for treating narcolepsy and preparation method thereof |
| CN106074582A (en) * | 2016-07-12 | 2016-11-09 | 昆明学院 | 4 cyano group β D glucoside compounds purposes in the medicine preparing treatment anxiety neurosis |
| CN108066439A (en) * | 2017-12-24 | 2018-05-25 | 湖北藻上好生物科技有限公司 | A kind of preparation method of the reducing blood lipid native compound group based on solution fermentation |
Non-Patent Citations (4)
| Title |
|---|
| AKITA Y, ET AL.: "New assay method for surveying anti-emetic compounds from natural sources", 《NATURAL PRODUCTS SCIENCES》 * |
| EL-SEWEIDY MM, ET AL.: "Haemostatic risk factors in dyslipidemic rabbits: role of 10-dehydrogingerdione as a new hypolipemic agent", 《J THROMB THROMBOLYSIS》 * |
| LI QQ, ET AL.: "Combined administration of the mixture of honokiol and magnolol and ginger oil evokes antidepressant-like synergism in rats", 《ARCH PHARM RES》 * |
| 毛跟年 等: "茯苓皮总三萜的降血脂活性研究", 《陕西科技大学学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112138053A (en) * | 2020-11-05 | 2020-12-29 | 西北民族大学 | A pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, and its preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109045045B (en) | 2020-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shen et al. | Policosanol: Extraction and biological functions | |
| Abo-elmatty et al. | Antioxidant and anti-inflammatory effects of Urtica pilulifera extracts in type2 diabetic rats | |
| Thirumalai et al. | Hypolipidemic activity of Piper betel in high fat diet induced hyperlipidemic rat | |
| Pan et al. | Dietary Fructus Schisandrae extracts and fenofibrate regulate the serum/hepatic lipid-profile in normal and hypercholesterolemic mice, with attention to hepatotoxicity | |
| KR101620077B1 (en) | Composition for Improving, Preventing or Treating Metabolic Diseases comprising Extracts from Borage officinalis | |
| WO2014058142A1 (en) | Pharmaceutical composition containing aster glehni extract as active ingredientfor preventing or treating obesity or metabolic diseases | |
| CN107405376A (en) | NASH improves or prevention composition | |
| AU2014333401A1 (en) | A medicinal composition of extract of seed of Emblica officinalis and method of preparing the same | |
| JP2012515139A (en) | GIP elevation inhibitor | |
| Zhou et al. | DHA‐enriched phosphatidylserine ameliorates high‐fat diet‐induced kidney injury in mice possibly by regulating TLR4/NF‐κB and AMPK pathways | |
| CN109045045A (en) | A kind of active ingredient of Chinese herbs composition for treating cardiovascular and cerebrovascular disease | |
| WO2018202107A1 (en) | Pharmaceutical composition for treating hyperlipidemia and atherosclerosis | |
| CN101850039B (en) | Composition with auxiliary lipid-lowering function | |
| KR101445966B1 (en) | A composition comprising Amomum cardamomum L. extracts having anti-obesity activity | |
| JP4325908B2 (en) | Lipolysis accelerator, skin external preparation and food and drink using the same | |
| JP6935285B2 (en) | Pharmaceutical composition | |
| JP2007031302A (en) | Adiponectin production accelerator and metabolic syndrome preventive | |
| US11957726B2 (en) | Pharmaceutical composition for controlling blood sugar | |
| JP3495694B2 (en) | Crude drugs and their extracts, foods, quasi-drugs, and pharmaceuticals consisting of ginseng, ginseng, and ginseng | |
| US20190290715A1 (en) | Açai berry seed extract, fractions of açai berry seed extracts, process for obtaining açai berry seed extracts, pharmaceutical and food compositions and method for the treatment of diseases or disorders with açai berry seed extract | |
| Deng et al. | Co-activating the AMPK signaling axis by low molecular weight fucoidan LF2 and fucoxanthin improves the HFD-induced metabolic syndrome in mice | |
| JP7068803B2 (en) | Pharmaceutical composition for reducing blood lipids | |
| KR100573592B1 (en) | Imperatae rhizoma Extract for Treatment and Prevention of Obesity | |
| JP5122924B2 (en) | Anti-obesity agent | |
| JP2003040795A (en) | Antihyperlipidaemic composition and method for manufacturing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220624 Address after: 215200 workshop 1, yunchuang Road, both sides of Shunfeng Road, Wujiang Economic and Technological Development Zone, Suzhou, Jiangsu Province Patentee after: SUZHOU LICHEN BIOTECHNOLOGY Co.,Ltd. Address before: 710026 No. B49, Xinda Zhongchuang space, 26th Street, block C, No. 2 Trading Plaza, South China City, international port district, Xi'an, Shaanxi Province Patentee before: Xi'an Huaqi Zhongxin Technology Development Co.,Ltd. Effective date of registration: 20220624 Address after: 710026 No. B49, Xinda Zhongchuang space, 26th Street, block C, No. 2 Trading Plaza, South China City, international port district, Xi'an, Shaanxi Province Patentee after: Xi'an Huaqi Zhongxin Technology Development Co.,Ltd. Address before: Huainan Normal University, Dongshan West Road, tianjia'an District, Huainan City, Anhui Province Patentee before: HUAINAN NORMAL University |